PsychedelicNewsBreaks – Marijuana Company of America Inc. (MCOA) Improves Patent Pending hempSMART Brain Product Formulation

Marijuana Company of America (OTC: MCOA) functions as an umbrella company supporting an assortment of portfolio businesses operating in the legal cannabis and hemp industry. In June, the company announced that its hempSMART™ brand relaunched its flagship patent pending product, hempSMART™ Brain. An article further discussing the product reads: “The improved formulation includes 300mg per bottle of full spectrum, non-psychoactive, water soluble CBD (10mg per serving), along with a botanical blend of all-natural plant-based ingredients. To learn more about the hempSMART™ Brain product, read the full press release (http://cnw.fm/2dKSp). The brand offers a line of CBD products and the opportunity to distribute the products as part of an affiliate network marketing model.”

To view the full article, visit http://cnw.fm/T4E4i

About Marijuana Company of America, Inc.

MCOA is a corporation which participates in: (1) product research and development of legal hemp-based consumer products under the brand name “hempSMART™”, that targets general health and well-being; (2) an affiliate marketing program to promote and sell its legal hemp-based consumer products containing CBD; (3) leasing of real property to separate business entities engaged in the growth and sale of cannabis in those states and jurisdictions where cannabis has been legalized and properly regulated for medicinal and recreations use; and, (4) the expansion of its business into ancillary areas of the legalized cannabis and hemp industry, as the legalized markets and opportunities in this segment mature and develop. For more information, visit the company’s website at www.MarijuanaCompanyofAmerica.com.

More from PsychedelicNewsBreaks

• PsychedelicNewsBreaks – Psychedelic Therapeutics and Drug Development Conference Partners with PsychedelicNewsWire as Official Media Sponsor
• PsychedelicNewsBreaks – 4th Annual Psychedelic Therapeutics and Drug Development Conference to Bridge Gaps in Research and Development of Therapeutic Psychedelics
• PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Enters Agreement to Conduct Clinical Trial to Assess Safety, Efficacy of unbuzzd(TM)

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) PsychedelicNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, PNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. PNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, PNW brings its clients unparalleled visibility, recognition and brand awareness. PNW is where news, content and information converge.

For more information please visit https://www.psychedelicnewswire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.psychedelicnewswire.com/disclaimer/

PsychedelicNewsWire (PNW)
San Francisco, California
www.psychedelicnewswire.com
415.949.5050 Office
Editor@PsychedelicWire.com